#United States #New York #Gross Law Firm #ESSA Pharma #EPIX

Class Action Lawsuit Against ESSA Pharma Inc.

On February 10, 2025, The Gross Law Firm announced a notice regarding a potential class action lawsuit against ESSA Pharma Inc. (NASDAQ: EPIX). This notice is particularly relevant for shareholders who purchased shares of the company during a specified class period, which extends from December 12, 2023, to October 31, 2024.

Understanding the Allegations

The complaint against ESSA alleges that the defendants made materially false or misleading statements, particularly concerning the efficacy of masofaniten when used in combination with enzalutamide for treating prostate cancer. The lawsuit claims that the combination therapy did not provide the anticipated benefits over enzalutamide alone, contradicting the company's prior assertions. Furthermore, it suggests that these misrepresentations led investors to overestimate the therapeutic potential and regulatory prospects of masofaniten, ultimately resulting in inflated stock prices based on unfounded expectations.

Several specific assertions are laid out in the complaint:
1. Lack of Efficacy Benefits: The combination therapy reportedly failed to deliver the clear efficacy benefits that were communicated to investors.
2. Study's Primary Endpoint: The M-E Combination Study, which investigated both monotherapy and combination therapy for prostate cancer, was unlikely to fulfill its primary endpoint defined in Phase 2.
3. Misleading Public Statements: Defendants are accused of issuing public statements that were false and misleading during the class period, causing shareholders to incur significant financial losses.

Important Dates and Next Steps

Shareholders who believe they may be affected are encouraged to act swiftly. The deadline to register for participation in the class action is March 25, 2025. Registering does not require shareholders to commit to a lead plaintiff role, and they can still be eligible for damages even if they choose not to take this on.

Next steps for interested shareholders involve registering with The Gross Law Firm. Once registered, they will benefit from a monitoring system that will keep them updated throughout the legal proceedings. This service comes at no cost, making it a crucial opportunity for those impacted.

For those considering registration, further information can be accessed via the Gross Law Firm's dedicated page.

Why Choose The Gross Law Firm?

The Gross Law Firm prides itself as a leading national firm specializing in class action lawsuits aimed at protecting investors’ rights. Their mission is to ensure that companies adhere to ethical business practices while seeking justice for investors who have suffered due to unethical or misleading behavior by corporate entities. The firm emphasizes consumer protection and is dedicated to recovering lost investments through legal action.

If you have incurred losses related to your investment in ESSA Pharma and wish to pursue your rights, don’t hesitate to reach out. The period for action is limited, and early registration may increase your chances of recovery should the lawsuit prove successful.

For direct inquiries, shareholders can contact The Gross Law Firm at their New York office located at 15 West 38th Street, 12th floor, New York, NY, 10018, or call at (646) 453-8903. They also offer the option of email communication for convenience.

In conclusion, shareholder vigilance is paramount. Those who took part in the class period of EPIX should evaluate their positions and act before the March 25, 2025 deadline to ensure they are not disadvantaged.